Table IV.

Multivariate analysis of clinical outcomes on total therapy 2 (TT2) (both arms) according to pretreatment variables inclusive of gene expression profiling (GEP)-defined risk category.

		Overall survival		Event-free survival		CR duration
70 gene-defined GEP high-risk	44/334 (13%)	2.93 (1.84, 4.68)	<0.001	2.47 (1.77, 3.45)	<0.001	20/174 (11%)	2.59 (1.41, 4.76)	0.002
Cytogenetic abnormalities	108/334 (32%)	1.93 (1.31, 2.86)	<0.001	NS2	NS2		NS2	NS2
Creatinine ≥2.0 mg/dl	37/334 (11%)	1.72 (1.05, 2.81)	0.033	1.78 (1.25, 2.54)	0.001		NS2	NS2
LDH ≥190 U/l	114/334 (34%)	1.59 (1.08, 2.35)	0.019	1.37 (1.09, 1.74)	0.008		NS2	NS2
Randomization to thalidomide	166/334 (50%)	NS2	NS2	0.75 (0.60, 0.93)	0.008		NS2	NS2

Results given as Hazard Ratio (95% confidence intervals) P-value from Wald chi-square test in Cox regression.

NS2 – Multivariate results not statistically significant at 0.05 level.

Multivariate model uses stepwise selection with entry level 0.1 and variable remains if it meets the 0.05 level.

Other variables considered for OS and EFS: age, Hb, CRP, albumin and B2M; for CR duration: creatinine, B2M and cytogenetic abnormalities.